<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426035</url>
  </required_header>
  <id_info>
    <org_study_id>MPSEMS0110_cream</org_study_id>
    <nct_id>NCT01426035</nct_id>
  </id_info>
  <brief_title>Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate Cream In The Superficial Varicose Veins Treatment</brief_title>
  <official_title>Phase III of Safety and Efficacy Study of Topic Mucopolysaccharide Polysulfate Cream 5mg/g in the Superficial Varicose Veins Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety, tolerability and effectiveness of mucopolysaccharide polysulfate cream
      in the treatment of superficial varicose veins
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study suspended by decision strategically.
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy - Symptoms reduction</measure>
    <time_frame>Evaluation time: 15 days treatment</time_frame>
    <description>The primary outcome measure will be evaluated for: Lesion area reduction, reduction of symptoms time and edema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - patient evaluation</measure>
    <time_frame>Evaluation time: 15 days treatment</time_frame>
    <description>The secondary outcome measure will be measured by subjective opinion (daily register).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>VARICOSE VEINS</condition>
  <arm_group>
    <arm_group_label>GROUP 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G</intervention_name>
    <description>APLIED 4 TIMES/DAY AT LESION</description>
    <arm_group_label>GROUP 1</arm_group_label>
    <arm_group_label>GROUP 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be able to understand the study procedures, agree to participate, and
             give written consent.

          -  Patients must be able to follow the study medication regimen.

          -  Patients with inflammatory process in superficial veins for more than 72 hours.

          -  Presence of symmetric lesions to compare one side to the other.

        Exclusion Criteria:

          -  Pregnancy or risk of pregnancy.

          -  Lactation.

          -  Use of topical or systemic anti-inflammatory, antihistamine or immunosuppressive drugs
             within the last 48 hours prior to the study

          -  Any alteration at other deep veins.

          -  History of atopy or allergic diseases.

          -  History of allergy to any component of the formulations.

          -  Other conditions considered by the investigator as reasonable for non-eligibility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FLAVIA ADDOR</last_name>
    <role>Principal Investigator</role>
    <affiliation>MEDCIN INSTITUTO DA PELE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Pinho, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medcin Instituto Da Pele</name>
      <address>
        <city>Osasco</city>
        <state>SÃ£o Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2011</study_first_posted>
  <last_update_submitted>March 1, 2013</last_update_submitted>
  <last_update_submitted_qc>March 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SUPERFICIAL VARICOSE VEINS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparinoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

